Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Bevacizumab with Y^90 Radioembolization for HCC Prior to Liver Transplantation
NCT07059494Phase 4Recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Mar 2026
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of atezolizumab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by Icahn School of Medicine at Mount Sinai. Started Mar 2026; status: recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07059494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07059494.